Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, successfully completed the first closing of its Series B financing round, securing $17.4 million. Geneva-based STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an … Read More
PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology … Read More
PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND – 9 January 2023, STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology … Read More